Christophe Plisson
Overview
Explore the profile of Christophe Plisson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hognasbacka A, Poot A, Plisson C, Bergare J, Bonsall D, McCluskey S, et al.
EJNMMI Res
. 2024 Feb;
14(1):19.
PMID: 38363422
Background: Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine kinase inhibitors target the mutation site in the ATP binding...
2.
Mercier J, Bani M, Colson A, Germani M, Lalla M, Plisson C, et al.
Mol Imaging Biol
. 2023 Dec;
26(2):310-321.
PMID: 38110790
Purpose: Minzasolmin (UCB0599) is an orally administered, small molecule inhibitor of ASYN misfolding in development as a potential disease-modifying therapy for Parkinson's disease. Here we describe the preclinical development of...
3.
Cook B, Nag S, Arakawa R, Lin E, Stratman N, Guckian K, et al.
J Nucl Med
. 2023 Nov;
64(10):1588-1593.
PMID: 37934021
-GlcNAcylation is thought to play a role in the development of tau pathology in Alzheimer's disease because of its ability to modulate tau's aggregation propensity. -GlcNAcylation is regulated by 2...
4.
Cook B, Archbold J, Nasr K, Girmay S, Goldstein S, Li P, et al.
Mol Imaging Biol
. 2022 Jun;
24(6):940-949.
PMID: 35655109
Purpose: The treatment of complex neurological diseases often requires the administration of large therapeutic drugs, such as antisense oligonucleotide (ASO), by lumbar puncture into the intrathecal space in order to...
5.
Cesarec S, Edgar F, Lai T, Plisson C, White A, Miller P
Dalton Trans
. 2022 Mar;
51(13):5004-5008.
PMID: 35293415
A novel radiolabelling method exploiting C-dithiocarbamate ligands has been used to generate C-labelled Au(I), Au(III), Pd(II) and Pt(II) complexes in high radiochemical yields (71-99%). Labelled complexes were prepared in a...
6.
Kee C, Tack O, Guibbal F, Wilson T, Isenegger P, Imiolek M, et al.
J Am Chem Soc
. 2020 Jan;
142(3):1180-1185.
PMID: 31913613
F labeling strategies for unmodified peptides with [F]fluoride require F-labeled prosthetics for bioconjugation more often with cysteine thiols or lysine amines. Here we explore selective radical chemistry to target aromatic...
7.
Onega M, Parker C, Coello C, Rizzo G, Keat N, Ramada-Magalhaes J, et al.
Eur J Nucl Med Mol Imaging
. 2020 Jan;
47(4):958-966.
PMID: 31897589
Purpose: Integrin αβ belongs to the RGD subset of the integrin family, and its expression levels are a prognostic and theranostic factor in some types of cancer and pulmonary fibrosis....
8.
McCluskey S, Plisson C, Rabiner E, Howes O
Eur J Nucl Med Mol Imaging
. 2019 Sep;
47(2):451-489.
PMID: 31541283
Purpose: A limit on developing new treatments for a number of central nervous system (CNS) disorders has been the inadequate understanding of the in vivo pathophysiology underlying neurological and psychiatric...
9.
Pagano G, Niccolini F, Wilson H, Yousaf T, Khan N, Martino D, et al.
Mov Disord
. 2019 Jun;
34(10):1505-1515.
PMID: 31158314
Background: Recent work has shown loss of phosphodiesterase 10A levels in middle-stage and advanced treated patients with PD, which was associated with motor symptom severity. Objectives: To assess phosphodiesterase 10A...
10.
McCluskey S, Haslop A, Coello C, Gunn R, Tate E, Southworth R, et al.
J Nucl Med
. 2019 Jun;
60(12):1750-1756.
PMID: 31147403
Many chemotherapy agents are toxic to the heart, such that increasing numbers of cancer survivors are now living with the potentially lethal cardiovascular consequences of their treatment. Earlier and more...